Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting VIP and PACAP Receptor Signalling: New Therapeutic Strategies in Multiple Sclerosis

1 Aug 2011

Abstract excerpt

MS (multiple sclerosis) is a chronic autoimmune and neurodegenerative pathology of the CNS (central nervous system) affecting approx. 2.5 million people worldwide. Current and emerging DMDs (disease-modifying drugs) predominantly target the immune system. These therapeutic agents slow progression and reduce severity at early stages of MS, but show little activity on the neurodegenerative component of the disease....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine receptors and signaling
Share to Neuropeptides and Animal Physiology
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21895607
DOI: 10.1042/an20110024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting VIP and PACAP Receptor Signalling: New Therapeutic Strategies in Multiple SclerosisPMID 21895607Read ↗

Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.Semantic proximity Read ↗

The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis.Semantic proximity Read ↗

From CGRP to PACAP: Unraveling the Next Chapter in Migraine TreatmentSemantic proximity Read ↗

Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.Semantic proximity Read ↗

Migraine Treatment: Towards New Pharmacological TargetsSemantic proximity Read ↗

PACAP and VIP increase the expression of myelin-related proteins in rat schwannoma cells: Involvement of PAC1/VPAC2 receptor-mediated activation of PI3K/Akt signaling pathwaysSemantic proximity Read ↗

Finding functional gaps: integrative analysis of VPAC1- and VPAC2-mediated signalling pathways in human lymphocytesSemantic proximity Read ↗

VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptorSemantic proximity Read ↗

Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.Semantic proximity Read ↗

The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory DiseasesSemantic proximity Read ↗

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal systemSemantic proximity Read ↗

VIP: a very important peptide in T helper differentiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.